Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Promoter hypermethylation may be a reversible mechanism (via DNA methyltransferase 1 inhibition) of resistance to GPRC5D-directed therapy in multiple myeloma based on pre-clinical data.”
Title: Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma
Authors: Seungbin Han, Umair Munawar, Marietta Truger, Elena Gerhard-Hartmann, Christina Verbruggen, Leila Pfeiffer, Ann-Sophie Hainold, Shilpa Kurian, Silvia Nerreter, Emma Besant, Cornelia Vogt, Nina Rein, Max Köppel, Johanna Lehmann, Friederike Schmitt, Yoko Tamamushi, Xiang Zhou, Torsten Steinbrunn, Claudia Haferlach, Andreas Rosenwald, Hermann Einsele, Leo Rasche, Johannes M. Waldschmidt, and Martin K. Kortüm.
You can read the Full Article in Haematologica.
You can find more posts featuring Robert Orlowski on OncoDaily.
